Related Experiment Videos
Impaired lymphocyte transformation in minimal change nephropathy in remission
Abstract:
A group of 37 patients with minimal change nephropathy (MCN) in remission for a mean period of 4.9 years (range 0.25-10) and on no current treatment were found to have a lymphocyte response to the mitogen Concanavalin A which was significantly lower than normal (P less than 0.001). This reduction in lymphocyte transformation was mainly due to the 24 patients who had received in addition to steroids a course of cyclophosphamide from 1 to 12 years (mean 6.7 years) previously (P less than 0.005 when compared t normal). Although the lymphocyte response of the remaining group of 13 patients who had not been treated with cyclophosphamide was not significantly lower than normal, there were three whose lymphocyte response to Concanavalin A was below the normal range. Our findings indicate that remission of MCN may be accompanied by a persistence of the abnormal lymphocyte function which is present during the nephrotic phase, and that cyclophosphamide may cause or add to this defect by a long-term effect on lymphocytes.
Insights
Patients with minimal change nephropathy (MCN) in remission show reduced lymphocyte response to Concanavalin A. This defect may persist and be exacerbated by prior cyclophosphamide treatment, indicating long-term immune effects.
Area of Science:
- Immunology
- Nephrology
- Clinical Medicine
Background:
- Minimal change nephropathy (MCN) is a significant cause of nephrotic syndrome in children and adults.
- Lymphocyte dysfunction has been implicated in the pathogenesis of MCN during active disease.
- The long-term immunological consequences of MCN remission and its treatment remain incompletely understood.
Purpose of the Study:
- To investigate lymphocyte function in patients with minimal change nephropathy (MCN) in long-term remission.
- To assess the potential impact of previous cyclophosphamide treatment on lymphocyte responsiveness.
Main Methods:
- A cohort of 37 patients with MCN in remission and off treatment were studied.
- Lymphocyte transformation response to the mitogen Concanavalin A was measured.
- Patient data regarding prior steroid and cyclophosphamide treatment were analyzed.
Main Results:
- Patients with MCN in remission exhibited significantly lower lymphocyte response to Concanavalin A compared to normal controls (P < 0.001).
- This reduction was primarily observed in patients who had previously received cyclophosphamide (P < 0.005).
- A subset of patients not treated with cyclophosphamide also showed reduced lymphocyte response.
Conclusions:
- Remission of MCN may be associated with persistent abnormal lymphocyte function, mirroring that seen during active disease.
- Cyclophosphamide treatment may contribute to or cause long-term defects in lymphocyte function in MCN patients.
- These findings suggest potential long-term immunomodulatory effects of MCN therapies.